QUOTED. Nov. 30, 2018. Graham Mullis.
French diagnostics firm Novacyt made its second deal in recent months, to supply molecular assay panels to US-based Genesis Diagnostics. The company is intentionally pushing an aggressive deal strategy for 2018 to prepare for anticipated global-economy headwinds in 2019, CEO Graham Mullis explains here.
- Find out more: Novacyt Lands New US Supply Deal, Maps Path To Profitability